[Corrigendum] CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.

Subsequently to the publication of the above paper, an interested reader drew to the authors' attention that a pair of the data panels showing the results of Transwell invasion assays (specifically, the 'C4­2 / shCON' and the PC­3 / CON panels) featured in Fig. 3F on p. 927 contained overlapping sections, such that data that were intended to show the results from differently performed experiments appeared to have been derived from the same original source. The authors were able to re­examine their original data files, and realized that this figure had been inadverently assembled incorrectly. The revised version of Fig. 3, containing the correct representative image of the PC­3shCON group, is shown on the next page. The authors also noted that the statistics in Fig. 3G remained correct, and did not require correction on account of the error made in assembling this figure. Similarly, note that the correction made to this figure does not affect the overall conclusions reported in the paper. The authors are grateful to the Editor of Oncology Reports for allowing them the opportunity to publish this Corrigendum, and all the authors agree with its publication. They also apologize to the readership for any inconvenience caused. [Oncology Reports 45: 921­932, 2021; DOI: 10.3892/or.2021.7920].